Muscular Dystrophy: FDA Approves Drug Developed By This Company

Catalyst Pharmaceuticals Announces FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy.

In a significant development in the medical world, Catalyst Pharmaceuticals has reported that the Food and Drug Administration (FDA) has approved AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy. This approval has been granted to Santhera Pharmaceuticals.

Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle deg…